SCHEMBL4907138

SCHEMBL4907138

N#Cc1c(Cl)nc(N)nc1-c1cccc(OCc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 14/20 0.58
ADORA2A P29274 13/20 0.58
ADORA2B P29275 6/20 0.58
BACE1 P56817 1/20 0.52
MAPT P10636 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
IGF1R P08069 1/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
PPARG P37231 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
NCOA2 Q15596 1/20 0.46
NCOA1 Q15788 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SQOR Q9Y6N5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904046 0.87 ADORA1 (0.58) ADORA1ADORA2AADORA2BBACE1MAPT
SCHEMBL14413783 0.86 ADORA1 (0.65) ADORA1ADORA2AADORA2BMAPTRXFP1
SCHEMBL4905916 0.81 ADORA1 (0.77) ADORA1ADORA2AADORA2BMAPTRXFP1
SCHEMBL4909492 0.81 MAPT (0.51) ADORA1ADORA2AADORA2BMAPTRXFP1
SCHEMBL2569855 0.79 ADORA1 (0.77) ADORA1ADORA2AADORA2BMEN1KMT2A
SCHEMBL6444882 0.77 MGMT (0.57) ADORA1ADORA2ACYP1A2CYP2C9CYP2C19
SCHEMBL27631464 0.76 IGF1R (0.56) ADORA2ABACE1MAPTIGF1RNPSR1
SCHEMBL6446566 0.76 ADORA1 (0.63) ADORA1ADORA2AADORA2BSQOR
SCHEMBL1877640 0.75 BACE1 (0.49) ADORA1ADORA2AADORA2BBACE1IGF1R
SCHEMBL14413781 0.75 ADORA1 (0.52) ADORA1ADORA2AADORA2BALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA1 529/4885ADORA2A 837/4885ADORA2B 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.